Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Trial Status:  Active
Results 1-25 of 37 for your search:
Start Over
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GMPE, NCT01256801
Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000644921, UPCC-15107, 807010, NCT00923143
Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 7866, NCI-2013-01377, 135, P30CA015704, U19AT006028, NCT01922921
Safety Study Of Anakinra Combined With Chemotherapy And Dendritic Cell Vaccine to Treat Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 013-154, NCT02018458
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0139, NCT02019524
Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 to 75
Sponsor: Other
Protocol IDs: CLB-001, 201401, NCT02063893
Vaccination of High Risk Breast Cancer Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 202556, NCT02229084
A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 03114, NCT02336984
Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18 to less than 80
Sponsor: Other
Protocol IDs: breast cancer MV, NCT02338804
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 030040, 03-C-0040, NCI-03-C-0040, NCI-5762, 5762, NCT00053170, NCT00048893
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J0947 CDR0000653173, P30CA006973, JHOC-J0947, NA_00024527, GENENTECH-JHOC-J0947, J0947, NCT00971737
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 368255, 1137008 / 20130058, NCT01570036
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2014-0443, NCT02297698
A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: QI-Breast Vaccine 1, NCT00715832
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CL-PTL 101, NCT01061840
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-09138, NCI-2011-00920, NCT01376505
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00034612, NCT01526473
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130016, 13-C-0016, NCT01730118
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 818561, 26113, NCT02061423
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 818532, 25113, NCT02063724
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ID-LV305-2013-001, NCT02122861
Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: MUC-1, NCT02140996
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 9140, NCI-2014-01070, 137, P30CA015704, NCT02157051
MVX-ONCO-1 in Patients With Solid Tumor
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MVX-2011-01, NCT02193503
Start Over